Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 6/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.54 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.53 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.53 |
| ▸ | CPT1A | P50416 | 5/20 | 0.47 |
| ▸ | CPT1B | Q92523 | 4/20 | 0.47 |
| ▸ | CPT2 | P23786 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2001054 | 0.90 | CNR1 (0.57) | RORCCNR1CNR2NR1I2NR1H2 | |
| SCHEMBL1998496 | 0.88 | CNR1 (0.68) | RORCCNR1CNR2NR1I2NR1H2 | |
| SCHEMBL1998173 | 0.87 | CNR1 (0.52) | RORCCNR1CNR2NR1I2NR1H2 | |
| SCHEMBL1996586 | 0.86 | CNR1 (0.54) | RORCCNR1CNR2NR1I2NR1H2 | |
| SCHEMBL1999022 | 0.85 | CNR1 (0.53) | RORCCNR1CNR2NR1I2NR1H2 | |
| SCHEMBL1999370 | 0.85 | CNR1 (0.57) | RORCCNR1CNR2NR1I2NR1H2 | |
| SCHEMBL1995905 | 0.84 | CNR1 (0.49) | RORCCNR1CNR2NR1I2NR1H2 | |
| SCHEMBL1997510 | 0.84 | POLB (0.50) | RORCCNR1CNR2NR1I2NR1H2 | |
| SCHEMBL4062546 | 0.81 | RORC (0.53) | RORCCNR1CNR2NR1I2NR1H2 | |
| SCHEMBL2000050 | 0.81 | CNR1 (0.53) | RORCCNR1CNR2NR1I2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960376-B2 | Benzo-fused heterocycles | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090075973-A1 | BENZO-FUSED HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075973-A1 | BENZO-FUSED HETEROCYCLES | CNR1, CNR2, TRPV1 | RORC 21/4885CNR1 1/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.